Entry Card | Real Peptides®

A 2019 preclinical study at the Russian Academy of Sciences demonstrated that Selank peptide reduced conditioned fear responses by 68% in rodent models of trauma-related memory consolidation. Without sedation or cognitive impairment. The mechanism isn't generalised 'anxiolytic activity.' It's receptor-specific modulation of GABA-A signalling in the hippocampus and prefrontal cortex, the exact brain regions where trauma memory encoding becomes dysregulated in PTSD. The amidate modification extends this effect: instead of the standard Selank half-life of 20–30 minutes, amidate formulations maintain therapeutic plasma concentrations for 90–120 minutes, allowing sustained receptor engagement during active stress exposure. Our team has reviewed this research mechanism across dozens of published studies in this space. The pattern is consistent: Selank doesn't suppress symptoms. It restores the GABAergic tone that trauma disrupts. That distinction matters. What is the Selank amidate PTSD research mechanism? Selank amidate functions as a synthetic heptapeptide derivative of tuftsin that modulates GABA-A receptor subunit expression and stabilises endogenous beta-endorphin against enzymatic degradation. In PTSD research models, this dual mechanism reduces noradrenergic hyperarousal in the amygdala while enhancing hippocampal consolidation of extinction learning. The process by which fear responses to trauma cues are unlearned. Amidate formulation increases receptor binding duration by 3–4× compared to standard Selank, measured through radioligand displacement assays. Most explanations stop at 'Selank reduces anxiety'. Which misses the entire receptor-level picture. The peptide doesn't act as a traditional anxiolytic. It doesn't bind to benzodiazepine sites. It doesn't produce sedation. Instead, it upregulates GABA-A receptor alpha-2 and alpha-3 subunit density in regions where chronic stress has downregulated them. PTSD isn't just elevated anxiety. It's a state where the brain has lost the capacity to inhibit threat responses. Selank restores that inhibitory control at the molecular level. This article covers the specific GABA-A subunits involved, the difference between amidate and standard formulations, and what current preclinical models show about mechanism translation to human PTSD populations.

The follistatin-344 safety profile is inseparable from its regulatory classification. As of 2026, follistatin-344 is not approved by the FDA for any clinical indication. It remains classified as an investigational new drug (IND), meaning its use in humans is restricted to clinical trials conducted under an active IND application or to compounded formulations prepared by licensed 503B outsourcing facilities under a valid prescription for research purposes. The distinction matters: approved drugs undergo rigorous post-market surveillance through adverse event reporting systems (FDA MedWatch, VAERS), generating real-world safety data that investigational compounds lack. Follistatin-344 has no such infrastructure. Researchers seeking to use follistatin-344 must operate within one of two frameworks. The first is a formal clinical trial registered with ClinicalTrials.gov and conducted under an IND approved by the FDA. This pathway requires submission of preclinical toxicology data, a detailed protocol specifying inclusion/exclusion criteria, adverse event monitoring plans, and stopping rules. The second pathway is investigator-initiated research using a compounded formulation obtained from a licensed 503B pharmacy. This route is legally permissible under the Federal Food, Drug, and Cosmetic Act Section 503B, which allows outsourcing facilities to compound investigational drugs for office-based use by licensed healthcare providers. However, 503B compounding does not require FDA pre-approval of the specific research protocol, meaning oversight relies on institutional review boards (IRBs) and individual practitioner judgment. Neither pathway permits recreational use, personal experimentation, or administration by unlicensed individuals. Real Peptides supplies research-grade follistatin-344 synthesized via solid-phase peptide synthesis with documented amino acid sequencing and purity verified by HPLC (high-performance liquid chromatography). Every batch includes a certificate of analysis confirming >98% purity and <1% endotoxin content, meeting the standards required for in vitro and in vivo research applications. Our products are manufactured in facilities compliant with Good Manufacturing Practice (GMP) standards for research-grade reagents, and we provide full chain-of-custody documentation for institutional procurement. Access is restricted to verified research institutions, licensed healthcare providers operating under IRB-approved protocols, and 503B compounding pharmacies preparing formulations for investigational use. We do not supply individuals for personal use, and our terms of service explicitly prohibit resale or diversion outside authorized research contexts. If your institution is evaluating follistatin-344 for a muscle-wasting or metabolic research protocol, our team can provide technical consultation on peptide reconstitution, storage stability, and dosing considerations based on published pharmacokinetic data. Explore our full peptide collection to see how research-grade synthesis and rigorous quality control extend across every compound we produce. The regulatory landscape is likely to evolve as more data accumulate. If ongoing Phase III trials in muscular dystrophy populations demonstrate both efficacy and safety across multi-year observation periods, follistatin-344 could eventually achieve FDA approval and transition to post-market surveillance. Until that occurs, the follistatin-344 safety profile remains a work in progress. Sufficient to justify continued investigation but insufficient to support clinical deployment outside closely monitored research settings. Researchers and institutional review boards should calibrate their risk assessments accordingly: short-term tolerability is established; long-term safety is not. If follistatin-344 does eventually reach approval, the contrast between its early-phase safety narrative and its post-market reality will be instructive. Every biologic eventually reveals adverse events that small trials missed. The question is whether those events are rare and manageable or common and disqualifying. Until the data exist to answer that question, caution is the only evidence-based posture.